There are lots of data points that seem to confirm the overseas clinical trials, a near-term launch of the HCV combo trial and the Duke/Gates/HIV alliance. Also hear that the cancer trial is going quite well and a top-line progress report may be available long before year end.
Regarding Influenza, however, there are good reasons to believe we will learn the "go/no-go" decision in late Sept. but it is just hope and speculation on my part that we will get a green light.
I agree with your view that most of the shorting comes from hedging by those who are accumulating. Hopefully a series of back-to-back PRs in Sept will convince those funds to cover and raise the bar on the trading range where the next round of accumulation occurs.
All IMO
News 
Market Data 
Discover 
